Pretoria High Court: Cipla HIV Tender Ruling Forces SA ARV Reassessment

• The Pretoria High Court ordered the Department of Health to re-evaluate a R12.6 billion portion of a R15.5 billion ARV tender due to multiple irregularities.
• Cipla Medpro Manufacturing challenged the awards after receiving only minor contracts, leading to the court's decision.
• Innovata Pharmaceuticals and Viatris Healthcare were disqualified for lacking valid manufacturing licenses at the time of bid closure.
• Barrs Pharmaceuticals and Aurobindo Pharma's bid prices must be adjusted due to unproven local manufacturing preference, while Innovata and Barrs also had unverified HDI claims.
• The Department of Health must investigate potential collusion between Innovata and Barrs, with current suppliers continuing deliveries to prevent drug shortages.

This significant ruling, delivered by Acting Judge Graham Girdwood, found multiple irregularities in the allocation of contracts for the one-month and three-month fixed-dose combination packs, declaring the initial awards unlawful and unconstitutional.

The Department of Health in South Africa has received a directive from the Pretoria High Court to reassess the awards made under a substantial tender for antiretroviral (ARV) medications. This significant ruling, delivered by Acting Judge Graham Girdwood, found multiple irregularities in the allocation of contracts for the one-month and three-month fixed-dose combination packs, declaring the initial awards unlawful and unconstitutional. The tender, valued at R15.5 billion in total, with R12.6 billion specifically for these combination packs, came into effect in December 2025 and is crucial for the supply of Tenofovir, lamivudine, and dolutegravir—the primary ARV regimen for adults in the country.

Local pharmaceutical company Cipla Medpro Manufacturing, a key supplier in the market, initiated the legal challenge after securing only R215 million in smaller awards and failing to win contracts for the larger one-month or three-month packs. Hetero Drugs South Africa, another unsuccessful bidder, also sought reconsideration of its own bid. The court has ordered the Department of Health to complete the re-evaluation and re-award process for these specific items within 120 days. To prevent any disruption in patient care, current suppliers will continue their deliveries, and the setting aside of the original awards will only become effective 90 days after the new contracts are finalized, ensuring a seamless transition to the newly appointed providers.

Judge Girdwood’s comprehensive judgment highlighted several critical non-compliance issues that led to the setting aside of the awards. A primary concern involved Innovata Pharmaceuticals and Viatris Healthcare, whose bids were explicitly excluded from any future reconsideration. The court found that these companies lacked valid manufacturing licenses for their Isando-based facility at the time the bids closed, with the judge unequivocally stating that an expired license does not constitute a valid one. This failure meant they should not have progressed beyond the initial stages of the tender adjudication process.

Further irregularities included issues with local manufacturing preference and claims of Historically Disadvantaged Individual (HDI) ownership. The court mandated that the final bid prices for Barrs Pharmaceuticals and Aurobindo Pharma be reverted to their pre-negotiation levels, as they did not meet the criteria for local manufacturing preference. Additionally, the scores of Innovata and Barrs were ordered to be adjusted because they had been awarded HDI points without providing sufficient proof of the ownership they claimed. The judgment also revealed that Innovata and Barrs, both subsidiaries of Avacare, had entered business rescue in December 2025, with Barrs experiencing stockouts of supplied items shortly thereafter. Consequently, the Department of Health has been directed to investigate potential collusion between Innovata and Barrs regarding their respective bids.

This Cipla HIV tender court ruling in South Africa carries profound implications, particularly given the essential nature of the ARV medications involved. Millions of South Africans rely on these drugs daily, often consumed as a single pill, making consistent supply critical to prevent life-threatening stockouts. The court’s decision to set aside the awards underscores the imperative for stringent adherence to procurement regulations and ethical bidding practices within the pharmaceutical sector.

The judgment reinforces the principle that public tenders, especially those concerning vital healthcare supplies, must be conducted with absolute transparency and compliance. It serves as a significant precedent for future public procurement processes in South Africa, emphasizing that procedural irregularities, such as invalid manufacturing licenses, unsubstantiated local preference claims, or unverified HDI status, will lead to the nullification of awards. The ruling ensures that while the tender process is rectified, the health of the nation's ARV patients remains protected through the continued supply by existing providers, mitigating immediate risks to public health.

Lawyers advising pharmaceutical companies on public tenders must scrutinize bid compliance, particularly regarding valid manufacturing licenses, local preference claims, and HDI status, as courts will set aside awards based on procedural irregularities. Compliance officers should review internal tender submission processes to mitigate risks of disqualification or successful challenge.

Source: Original reporting via Moneyweb